About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Melanoma Clinical Trials | 1,292 Studies Recruiting | Clareo Health

Clinical TrialsMelanoma

Melanoma Clinical Trials

Browse 1,292 clinical trials for melanoma. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1121-1140 of 1,292 trials

COMPLETEDPhase 1

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

NCT00920907

The purpose of this clinical research study is to compare pharmacokinetics of ipilimumab manufactured by two different processes

Advanced Melanoma

Bristol-Myers Squibb99 participantsStarted Aug 2009

Los Angeles, California, United States • San Francisco, California, United States • Tampa, Florida, United States +4 more locations

COMPLETEDPhase 2

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

NCT00623766

To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.

Bristol-Myers Squibb99 participantsStarted Jul 2008

Scottsdale, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +11 more locations

Related Searches

skin cancertrials

Data from ClinicalTrials.govTerms

Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

NCT01068470

Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.

MelanomaKidney Cancer

Loma Linda University11 participantsStarted Nov 2009

Beaumont, California, United States

COMPLETEDPhase 2

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

NCT00003274

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known what preparation of vaccine therapy is most effective for treating melanoma. PURPOSE: Randomized phase II trial to study the effectiveness of tyrosinase/gp100 peptide vaccine in treating patients who have stage II melanoma that can be removed by surgery.

Melanoma (Skin)

University of Southern California48 participantsStarted Mar 1998

Los Angeles, California, United States • Ann Arbor, Michigan, United States

TERMINATEDPhase 2

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00006113

RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with biological therapy may kill more tumor cells. PURPOSE: This phase II trial is studying giving vaccine therapy together with interferon gamma and interleukin-2 in treating patients with stage III or stage IV melanoma.

Melanoma (Skin)

University of Southern California25 participantsStarted Jun 1999

Los Angeles, California, United States

COMPLETEDPhase 1

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

NCT00025181

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining monoclonal antibody therapy and vaccine therapy in treating patients who have stage III or stage IV melanoma that has been removed during surgery.

Intraocular MelanomaMelanoma (Skin)

University of Southern California19 participantsStarted Oct 2001

Los Angeles, California, United States

COMPLETEDPhase 2/3

A Randomized Control Trial of Sun Protection Interventions for Operating Engineers

NCT01804595

This is a randomized controlled trial testing the efficacy of 4 sun protection interventions--education only; education and mailed sunscreen; education and text message reminders; and education, mailed sunscreen, and text message reminders--among Michigan Operating Engineers. Pre- and post-intervention surveys will be collected to determine changes in sunscreen use and sun burning, the primary outcome variables. The investigators hypothesize that all interventions will increase sunscreen use and reduce burning and that the education-only intervention will have the least effect of the 4 interventions while the education, mailed sunscreen, and text messaging arm will have the greatest effect.

Skin Cancer Prevention

University of Michigan357 participantsStarted Feb 2012

Ann Arbor, Michigan, United States

COMPLETEDPhase 1

A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

NCT01066390

This phase I study plan is divided in the following four phases: * Eligibility Screen Phase (week -4 to -1): Following written informed consent patients with metastatic melanoma (AJCC stage III/IV with unresectable disease) will undergo an eligibility screen (incl. blood analysis and PET/CT-scan). * TriMix-DC Vaccine Manufacturing Phase (week I to IV): eligible patients will undergo a leucapheresis (15 liter of venous blood) for the preparation of autologous TriMix-DC vaccine. Vaccine preparations will be manufactured and quality-controlled (during an interval of 4 weeks following the leucapheresis) and released for patient administration if the TriMix-DC preparation fulfills the predefined quality requirements. * TriMix-DC Vaccine Administration Phase (Week 1 to 24): 4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks. At each vaccination a total of 12.106 DC per antigen will be administered. * Patients will be allocated to three different cohorts: * The first cohort will receive 10% of TriMix-DC by iv and 90% by id injection. * The second cohort 25% by iv and 75% by id injection. * The third cohort 50% by iv and 50% by id injection. * During the week following the administration of the fourth vaccine (= week 8), a DTH-test and punch biopsy of the injection site will be performed as well as a second leucapheresis (for the purpose of immuno-monitoring) and tumor evaluation (by PET-CT). * A fifth vaccine will be administered and a repeat tumor staging performed in week 16 (= 8w after the fourth vaccine). * End of study visit: Patients will perform an "end of study visit" 8 weeks after the fifth vaccine (= week 24) as well as a new tumor evaluation (PET/CT). * Follow-up Phase: survival data will be obtained until 3 years after the initiation of vaccine therapy or the time of death.

Bart Neyns18 participantsStarted Dec 2009

Laken, Brussels Capital, Belgium

COMPLETEDPhase 2

Viral Therapy in Treating Patients With Metastatic Melanoma

NCT00651157

This phase II trial is studying the side effects and how well viral therapy works in treating patients with metastatic melanoma. Viral therapy may be able to kill tumor cells without damaging normal cells.

Recurrent MelanomaStage IV Melanoma

National Cancer Institute (NCI)23 participantsStarted Apr 2008

Rochester, Minnesota, United States

COMPLETEDPhase 1

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

NCT00349206

This phase I trial is studying the side effects and best dose of temsirolimus when given together with sorafenib and to see how well they work in treating patients with metastatic, recurrent, or unresectable melanoma. Sorafenib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with temosirolimus may kill more tumor cells.

MelanomaRecurrent MelanomaStage III Melanoma+1 more

National Cancer Institute (NCI)69 participantsStarted Apr 2006

Houston, Texas, United States

COMPLETEDPhase 2

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

NCT01014351

Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in efficacy as measured by progression-free survival and response rate.

Metastatic Melanoma

SCRI Development Innovations, LLC70 participantsStarted Feb 2010

Fort Myers, Florida, United States • Gainesville, Georgia, United States • Evansville, Indiana, United States +9 more locations

COMPLETEDPhase 2

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer

NCT00004135

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus peripheral stem cell transplantation in treating patients who have metastatic kidney cancer or melanoma.

Kidney CancerMelanoma (Skin)

University of Chicago19 participantsStarted Feb 1999

Chicago, Illinois, United States

COMPLETEDPhase 1/2

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

NCT00084214

This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.

Synta Pharmaceuticals Corp.103 participantsStarted May 2004

Hot Springs, Arkansas, United States • Little Rock, Arkansas, United States • San Diego, California, United States +25 more locations

TERMINATEDPhase 3

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

NCT00522834

"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells. This response is characterized by increased production of gene families that protect against different cellular stresses, including excessive heat, the presence of reactive oxygen species such as oxygen radicals, or the presence of heavy metals. Subjects will participate in up to 2 weeks of screening during which time they will complete all screening procedures. Eligible subjects who have not received any prior cytotoxic chemotherapeutic agent for melanoma will be randomized in a 1:1 ratio to receive either STA-4783 213 mg/m2 in combination with paclitaxel 80 mg/m2 or paclitaxel 80 mg/m2 alone. One treatment cycle will consist of weekly treatments for 3 weeks, followed by a 1-week rest period. Cycles will be repeated every 4 weeks until disease progression. Tumor assessments will be performed every 8 weeks from the date of randomization or sooner if the Investigator suspects progression has occurred based on clinical signs and symptoms. "

Synta Pharmaceuticals Corp.630 participantsStarted Aug 2007

Tucson, Arizona, United States • Little Rock, Arkansas, United States • La Jolla, California, United States +98 more locations

Cognitive Effects of Interferon in Patients With Melanoma

NCT02074605

Interferon alpha is the only approved adjuvant biologic therapy for individuals diagnosed with high risk malignant melanoma (stage 2 or 3). There is evidence that interferon has some adverse cognitive effects on patients, but there are limited data. The investigators hypothesis is that compared to patients with melanoma who do not receive interferon, patients who have melanoma and are treated with interferon will show an objective decrease in performance on neurocognitive assessment. This study will enroll patients with melanoma who qualify for interferon, and either decide to undergo interferon treatment or choose watchful waiting instead. All patients will be assessed with a cognitive testing battery twice. Observation patients will undergo testing at their first appointment in which they consent to the study, as well as at their next physician visit, approximately 3 months from the first visit. Interferon patients will be tested immediately prior to starting interferon, as well as immediately after completing high dose interferon.

University of Arizona36 participantsStarted Jul 2008

Tucson, Arizona, United States

TERMINATEDPhase 2

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

NCT01055522

This Phase II clinical study is an open-label, multicenter study of L19IL2 in combination with Dacarbazine in patients with metastatic melanoma. The study is divided in two parts: a phase IIa part, designed to establish the recommended dose (RD) of L19IL2 when administered in combination with a fixed dose of Dacarbazine, as well as to determine the preliminary tolerability profile; the second phase IIb part evaluates the objective response rate (ORR) including a randomized study with a fixed dose of Dacarbazine with or without L19IL2, dosed at the RD determined in phase IIa.

Metastatic Melanoma

Philogen S.p.A.102 participantsStarted Jun 2008

Graz, Austria • Berlin, Germany • Kiel, Germany +7 more locations

COMPLETEDPhase 2

Clinical Trial of Sutent to Treat Metastatic Melanoma

NCT00631618

The purpose of this study is to investigate whether an investigational drug called sunitinib malate is safe and effective in treating metastatic melanoma in patients with KIT mutations. KIT is a gene that "codes for" (contains the genetic code that the body uses to make) a protein on the surface of cells in your body that is important in cell growth and cell division. The KIT protein seems to play a role in abnormal cell growth seen in acute leukemia, germ cell tumors, gastrointestinal stromal tumors (GIST), and certain melanomas. Melanomas that arise on acral skin (palms, soles, nail beds), mucosal membranes, and chronically sun damaged skin have recently been found to frequently contain mutations or increased copy numbers of the KIT gene. Your tumor tissue has previously been tested and has been found to contain abnormalities in the KIT gene. Sunitinib malate is drug that has been shown to inhibit the activity of the KIT protein. The FDA approved sunitinib in 2006 for patients with GIST. It has been shown that sunitinib malate works in these patients because of its activity against the KIT protein. The FDA also approved Sunitinib malate in 2006 for the treatment of metastatic kidney cancer, where its effectiveness is probably due to its ability to block a different set of proteins. Sunitinib malate has not been approved by the FDA for the treatment of metastatic melanoma.

Metastatic Melanoma

California Pacific Medical Center Research Institute12 participantsStarted Sep 2007

San Francisco, California, United States

WITHDRAWNPhase 2

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

NCT01933061

A phase 2, open-label randomized, multicenter trial to compare CC-486 in combination with Abraxane administered weekly with respect to overall survival, objective tumor response rate and Progression-Free Survival (PFS) in participants diagnosed with metastatic malignant melanoma.

Metastatic Melanoma

Celgene CorporationStarted Jan 2014

COMPLETEDPhase 1/2

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

NCT00012064

RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV or recurrent melanoma.

Melanoma (Skin)

Lisata Therapeutics, Inc.56 participantsStarted Jul 2000

Newport Beach, California, United States

UNKNOWNPhase 1/2

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00002817

RATIONALE: Vaccines may make the body build an immune response to kill melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients with metastatic melanoma.

Melanoma (Skin)

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University30 participantsStarted Apr 1996

Philadelphia, Pennsylvania, United States

PreviousPage 57 of 65Next